PROCRITline.com - Patient Resources

Portal Home

For reimbursement information regarding other Centocor Ortho Biotech Inc. products, please click here.

PROCRITline.com Reimbursement Excellence

Introduction

Please see full Prescribing Information, including Boxed WARNINGS, for PROCRIT^® (Epoetin alfa)

Please see full Prescribing Information, including Boxed WARNINGS, for LEUSTATIN^® (cladribine)

PATIENT RESOURCES

Welcome

PROCRITline^® provides easy access to reimbursement information and support including:

	Benefit Verification
	Prior Authorization research
	Appeal process and procedure research
	Alternate sources of payment
	General billing and coding questions
	Information regarding patient assistance

THE INFORMATION PROVIDED REPRESENTS NO STATEMENT, PROMISE, OR GUARANTEE BY Centocor Ortho Biotech Inc. CONCERNING LEVELS OF REIMBURSEMENT. PLEASE CONSULT YOUR PAYOR ORGANIZATION WITH REGARD TO LOCAL OR ACTUAL COVERAGE AND REIMBURSEMENT POLICIES AND DETERMINATION PROCESSES.

PROCRIT^® (Epoetin alfa) Full Prescribing Information, including Boxed WARNINGS

Benefit Verification Form

Click here to view and to print the application for Insurance Benefit Verification for PROCRIT and LEUSTATIN. This form requires the Adobe Reader for viewing and printing.

LEUSTATIN^® (cladribine) Injection Full Prescribing Information, including Boxed WARNINGS

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF)

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, private, nonprofit organization that assists patients who do not have financial resources or prescription drug coverage obtain free prescription products that are donated by Johnson & Johnson operating companies. These companies have a long-standing commitment to helping patients access medicines. Centocor Ortho Biotech Inc. donates medicines to JJPAF.

To learn more about the JJPAF patient assistance programs or to apply for assistance, please visit the JJPAF website or call and speak to one of our patient assistance program specialists at 800-652-6227.

Important Safety Information for PROCRIT^® (Epoetin alfa)

WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE

Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious cardiovascular events, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of 13 g/dL and above.

Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1).

To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.

Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense PROCRIT^® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

Discontinue following the completion of a chemotherapy course.

Perisurgery: PROCRIT^® (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.

(See WARNINGS: Increased Mortality, Serious Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Please see full Prescribing Information, including Boxed WARNINGS for PROCRIT^® (Epoetin alfa)

Medication Guide for PROCRIT^®
Please read the Medication Guide for PROCRIT^® and discuss with your doctor.

Patient Instructions for Use
Instructions if you or your caregiver has been trained to give PROCRIT^® injections at home.

Boxed WARNINGS: LEUSTATIN^® (cladribine) Injection

LEUSTATIN (cladribine) Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received LEUSTATIN Injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens.

Acute nephrotoxicity has been observed with high doses of LEUSTATIN (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.

Please see full Prescribing Information, including Boxed WARNINGS for LEUSTATIN^® (cladribine)